Second Sight Medical Products Inc. (NASDAQ:EYES)’s share price dropped 1.2% during mid-day trading on Friday . The company traded as low as $3.96 and last traded at $4.05, with a volume of 492,095 shares trading hands. The stock had previously closed at $4.10.

Separately, Zacks Investment Research cut shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a research report on Monday, April 18th.

The stock’s 50-day moving average is $3.78 and its 200 day moving average is $4.63. The company’s market cap is $146.31 million.

Second Sight Medical Products (NASDAQ:EYES) last posted its earnings results on Thursday, April 28th. The medical device company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.38 million. The business’s revenue was down 38.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. On average, equities analysts forecast that Second Sight Medical Products Inc. will post ($0.65) EPS for the current fiscal year.

In other Second Sight Medical Products news, Chairman Robert J. Greenberg sold 8,223 shares of the stock in a transaction on Monday, April 18th. The shares were sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the transaction, the chairman now owns 181,134 shares in the company, valued at $954,576.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Robert J. Greenberg sold 8,571 shares of the stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the transaction, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Second Sight Medical Products stock. Zeke Capital Advisors LLC acquired a new stake in shares of Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, Holdings Channel reports. The firm acquired 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products accounts for approximately 2.5% of Zeke Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned about 1.38% of Second Sight Medical Products as of its most recent SEC filing.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.